Jimenez Freddy A.

SVP & GENERAL COUNSEL

Celldex Therapeutics, Inc.

US, Hampton [HQ]

CIK 1838114

Data Source

We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.

Latest Information

35,464

Price per Share :

$22.62

Equivalence :

$802,195.68

Transaction History

M

Form 4

35,464 Shares After Transaction

Value : $368,116.32

$99,025.20

Transaction Date : 06/05/24
- Footnotes
- Form 4
Footnotes:
No footnote found.
M

Form 4

33,930 Shares After Transaction

Value : $352,193.40

$83,102.28

Transaction Date : 06/03/24
- Footnotes
- Form 4
Footnotes:
No footnote found.
S

Form 4

25,924 Shares After Transaction

Value : $871,046.40

Sold $269,001.60

Transaction Date : 06/03/24
- Footnotes
- Form 4
Footnotes:
No footnote found.
M

Form 4

5,924 Shares After Transaction

Value : $53,434.48

$37,577.32

Transaction Date : 02/13/24
- Footnotes
- Form 4
Footnotes:
#1 On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

#2 Includes 1,328 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
M

Form 4

25,924 Shares After Transaction

Value : $72,068.72

$55,600.00

Transaction Date : 02/13/24
- Footnotes
- Form 4
Footnotes:
#1 On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.

#2 Includes 1,328 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.